CAR T-cell case study: Sequencing therapies for patients with high-risk DLBCL 

During the European Hematology Association (EHA) 2023 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint session entitled 'The ins and outs of CAR T-cells in the real world'.
Here, we share the presentation of Professor Ulrich Jäger, Medical University of Vienna, Vienna, AT, on the topic of sequencing therapies for patients with high-risk diffuse large B-cell lymphoma. Using a real-world patient case, Jäger provides a pre- and post-CAR T-cell therapy overview of the treatment regimen, outlining the patient eligibility criteria for CAR-T cell therapy according to the Austrian CAR T-cell Network.
This activity was supported through an educational grant from Bristol Myers Squibb.
Visit www.lymphomahub.com for more information on this topic.